Supporting information for Gordon et al. (2003) Proc. Natl. Acad. Sci. USA, 10.1073/pnas.0735266100

 

Table 6. B29 polymorphisms were found in all cells analyzed

Cell line

Polymorphisms

Nonhematopoetic

 

HeLa

G1068A (i1), G1518A (i2), T2453C (e3 Ig C122C),

ΔT2667 (i3), insT3101 (i4), G3525C (3'UTR), T3526C (3'UTR), C3698T (3'UTR)

T lymphocyte

 

Jurkat

G1636A (i2), G1722A (i2),

ΔT2667 (i3), C3461T (3'UTR), G3525C (3'UTR), T3526C (3'UTR)

preB

 

BLIN-1 †

Δ

G1839 (i2), T2453C (e3 Ig C122C), ΔT2667 (i3), C3698T (3'UTR)

Nalm6 †

T2453C

 (e3 Ig C122C), ΔT2667 (i3), insG3081 (i4), insT3101 (i4), C3698T (3'UTR)

Normal CD19- PBL*

 

Donor A

C988A (i1) 5/5 clones; A1068G (i1) 5/5 clones; T2453C (e3 Ig C122C) 2/5 clones; insG3081 (i4) 5/5 clones; C3461T (3'UTR) 5/5 clones; G3524C (3'UTR) 5/5 clones;

T3525C (3'UTR) 5/5 clones

Donor C

C988A (i1) 5/5 clones; T2453C (e3 Ig C122C) 5/5 clones;

ΔT3111 (i4) 2/5 clones

Donor D

T2453C

(e3 Ig C122C) 5/5 clones; insG3081 (i4) 3/5 clones; ΔT3111 (i4) 2/5 clones

Normal CD19+ PBL*

  

Donor A

C988A (i1) 10/10 clones; A1068G (i1) 10/10 clones; T2453C (e3 Ig C122C) 5/10 clones; insG3081 (i4) 10/10 clones; C3461T (3'UTR) 10/10 clones; G3524C (3'UTR) 10/10 clones; T3525C (3'UTR) 7/10 clones

Donor C

C988A (i1) 10/10 clones; T2453C (e3 Ig C122C) 10/10 clones;

ΔT3111 (i4) 7/10 clones

Donor D

T2453C

(e3 Ig C122C) 10/10 clones; insG3081 (i4) 5/10 clones; ΔT3111 (i4) 3/10 clones

Burkitt Lymphoma

 

BJAB

T2453C

 (e3 Ig C122C),ΔT2667 (i3), insG3081 (i4)

BL-2†

Δ

T2667 (i3), ΔT3101 (i4), C3461T (3'UTR), G3525C (3'UTR), T3526C (3'UTR)

BL-41

G1722A (i2), insG3081 (i4), C3461T (3'UTR)

CL-O1†

Δ

G1839 (i2), T2453C (e3 Ig C122C), ΔT2667 (i3), insG3081 (i4), G3525C (3'UTR), T3526C (3'UTR), C3461T (3'UTR), C3698T (3'UTR)

Ramos†‡

G1068A (i1), T2453C (e3 Ig C122C),

ΔT2667 (i3), insT3101 (i4)

DLBCL

 

NU DHL1

C988A (i1), G1636A (i2), G1722A (i2),

ΔG1839 (i2), ΔT2667 (i3), ΔA2685 (i3), insG3081 (i4), C3461T (3'UTR)

SU DHL5

T2453C

 (e3 Ig C122C), insG3081 (i4), C3461T (3'UTR), G3525C (3'UTR), T3526C (3'UTR), C3698T (3'UTR)

SU DHL6

G1068A (i1), T2453C (e3 Ig C122C),

ΔT2667 (i3), insG3081 (i4), insT3101 (i4)

SU DHL9

T2453C

 (e3 Ig C122C), ΔT2667 (i3), insG3081 (i4), G3525C (3'UTR), T3526C (3'UTR), C3698T (3'UTR)

OCI Ly1

G1518A (i2),

ΔT2667 (i3), insG3081 (i4), G3525C (3'UTR), T3526C (3'UTR), C3698T (3'UTR)

OCI Ly3

G1636A (i20), G1722A (i2), T2453C (e3 Ig C122C), C3698T (3'UTR)

OCI Ly7

G1068A (i1),

ΔT2667 (i3), ΔT3111 (i4), C3461T (3'UTR)

OCI Ly10

Δ

T2667 (i3), insG3081 (i4), insT3101 (i4), C3461T (3'UTR), G3525C (3'UTR), T3526C (3'UTR)

OCI Ly18

G1068A (i1), T2453C (e3 Ig C122C),

ΔT2667 (i3), insG3081 (i4), C3698T (3'UTR)

OCI Ly19

G1068A (i1), T2453C (e3 Ig C122C),

ΔT2667 (i3),

Hodgkin Lymphoma Reed-Sternberg

 

L428

G1068A (i1),

ΔT3111 (i4), T3526C (3'UTR)

PEL

 

BC1

G1068A (i1), G2660T (i3),

ΔA2685 (i3), ΔT3101 (i4)

BC3§

Δ

G1839 (i2), T2453C (e3 Ig C122C), ΔT2667 (i3), insG3081 (i4),

BCBL-1

G1636A (i20), G1722A (i2), insT3101 (i4),

ΔT3111 (i4), C3461T (3'UTR), G3525C (3'UTR), T3526C (3'UTR)

Myeloma

 

ANBL6

G1068A (i1), T2453C (e3 Ig C122C),

ΔT2667 (i3), insG3081 (i4),

EJM

G1518A (i2),

ΔG1839 (i2), T2453C (e3 Ig C122C), ΔT2667 (i3), insG3081 (i4), G3525C (3'UTR), T3526C (3'UTR)

HS-Sultan†

G1518A (i2), T2453C (e3 Ig C122C),

ΔT2667 (i3), insT3101 (i4), C3461T (3'UTR), G3525C (3'UTR), T3526C (3'UTR), C3698T (3'UTR)

Karpas 620

C988A (i1), G1636A (i20), G1722A (i2),

ΔT2667 (i3), C3461T (3'UTR), G3525C (3'UTR), T3526C (3'UTR)

KMS12

G1068A (i1),

ΔG1839 (i2), T2453C (e3 Ig C122C), ΔT2667 (i3), insT3101 (i4), insG3081 (i4)

L363

G1518A (i2),

ΔG1839 (i2), T2453C (e3 Ig C122C), insG3081 (i4), insT3101 (i4), ΔT3111 (i4), G3525C (3'UTR), T3526C (3'UTR), C3698T (3'UTR)

NCI-H929†

G1636A (i20), T2453C (e3 Ig C122C),

ΔT2667 (i3)

RPMI 8226

G1518A (i2), T2453C (e3 Ig C122C), G3525C (3'UTR), T3526C (3'UTR), C3698T (3'UTR)

The B29 gene was amplified and sequenced, and sequences were analyzed as described in Table 5. Sequence alteration swere defined as polymorphisms if found in cells that do not undergo somatic hypermutation. Coding region alterations in bold, the site of the alteration in the gene and protein in parentheses; ins, insertion; Δ

, deletion; i, intron; e, exon; FS, frameshift; Ig, immunoglobulin domain; tm, transmembrane domain; cyto, cytoplasmic domain; *, clones derived from PBLs of normal donors; †, confirmed by cDNA sequencing; ‡, unumutated Bcl6 (1); §, unmutated VH4 (2).

1. Bemark, M. & Neuberger, M. S. (2000) Oncogene 19, 3404–3410.

2. Matolcsy, A., Nador, R. G., Cesarman, E. & Knowles, D. M. (1998) Am. J. Pathol. 153, 1609–1614.